We are pleased to announce our newest publication titled “Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine” on CIR (https://lnkd.in/eMkyFK2c). We demonstrate that whilst multiple neoantigens in combination with checkpoint inhibitors are needed for efficacy in high disease burden settings, single epitopes can be effective in early disease burden models. To achieve effective and durable responses does require a platform with sufficient neoantigen capacity that is able to promote CD4 and CD8 T cell responses and epitope spreading. #cancervaccines #neoantigens #viralvectors #immunotherapy
Great job, Noucom, congratulations!
Congratulation to all the team!